Abalos Therapeutics raises €32.5M Series A round
14 October 2021· Düsseldorf, Germany· health, oncology, biotech, b2b, deep_hardware
The additional funds will enable the company to advance its first product candidate, ABX-001, into a Phase 1/2 trial in multiple solid tumors and to fund further pipeline expansion.
Investors
LeadSeventure Partners
Also participating
High-Tech GründerfondsNRW.BankCoparionGründerfonds RuhrBoehringer Ingelheim Venture FundVentura BioMed InvestorsHx Bio Ventures
About Abalos Therapeutics
Stage
Series A
Headquarters
Düsseldorf, Germany
Founded
2019
Team Size
21–50
Sectors
healthoncologybiotechb2bdeep_hardware